Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective. - Gogebakan KC; Kunst N; Ghodsi A; Owens L; Iravani A; Etzioni R (Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026)